Dose-intensive chemotherapy [cyclophosphamide + etoposide + rituximab + cytarabine + doxorubicin] combined with monoclonal antibody [tositumomab + iodine-131-tositumomab] therapy and targeted radioimmunotherapy for untreated patients with high-risk B-cell non-Hodgkin's lymphoma.

Trial Profile

Dose-intensive chemotherapy [cyclophosphamide + etoposide + rituximab + cytarabine + doxorubicin] combined with monoclonal antibody [tositumomab + iodine-131-tositumomab] therapy and targeted radioimmunotherapy for untreated patients with high-risk B-cell non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Rituximab; Tositumomab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2012 Planned end date changed from 1 Jun 2012 to 1 Feb 2021 as reported by ClinicalTrials.gov.
    • 13 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top